BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33377619)

  • 21. Huaier extract suppresses non-small cell lung cancer progression through activating NLRP3-dependent pyroptosis.
    Xie J; Zhuan B; Wang H; Wang Y; Wang X; Yuan Q; Yang Z
    Anat Rec (Hoboken); 2021 Feb; 304(2):291-301. PubMed ID: 31692261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway.
    Park JJ; Hwang SJ; Park JH; Lee HJ
    Cell Oncol (Dordr); 2015 Apr; 38(2):111-8. PubMed ID: 25561311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α.
    Wan J; Wu W; Huang Y; Ge W; Liu S
    Oncol Rep; 2016 Aug; 36(2):659-68. PubMed ID: 27278081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.
    He L; Zhang E; Shi J; Li X; Zhou K; Zhang Q; Le AD; Tang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):713-25. PubMed ID: 23292117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.
    Burrows N; Babur M; Resch J; Ridsdale S; Mejin M; Rowling EJ; Brabant G; Williams KJ
    J Clin Endocrinol Metab; 2011 Dec; 96(12):E1934-43. PubMed ID: 21994956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of HIF-1α inhibits the proliferation, migration, and invasion of gastric cancer by inhibiting PI3K/AKT pathway and VEGF expression.
    Zhang J; Xu J; Dong Y; Huang B
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 29899167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism.
    Wan X; Liu Y; Zhao Y; Sun X; Fan D; Guo L
    PLoS One; 2017; 12(9):e0184213. PubMed ID: 28886081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3β/β-catenin pathway.
    Yan X; Lyu T; Jia N; Yu Y; Hua K; Feng W
    PLoS One; 2013; 8(5):e63731. PubMed ID: 23667667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1α) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
    He H; Wang X; Chen J; Sun L; Sun H; Xie K
    Med Sci Monit; 2019 Apr; 25():2352-2360. PubMed ID: 30930461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
    Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
    Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.
    Ban HS; Kim BK; Lee H; Kim HM; Harmalkar D; Nam M; Park SK; Lee K; Park JT; Kim I; Lee K; Hwang GS; Won M
    Cell Death Dis; 2017 Jun; 8(6):e2843. PubMed ID: 28569777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway.
    Zhang L; Liu Q; Lu L; Zhao X; Gao X; Wang Y
    J Pharmacol Exp Ther; 2011 Aug; 338(2):485-91. PubMed ID: 21576377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
    Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIF-1α promotes inflammatory response of chronic obstructive pulmonary disease by activating EGFR/PI3K/AKT pathway.
    Zhang HX; Yang JJ; Zhang SA; Zhang SM; Wang JX; Xu ZY; Lin RY
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6077-6084. PubMed ID: 30280794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α.
    Lin S; Zhu B; Huang G; Zeng Q; Wang C
    Hum Cell; 2019 Jan; 32(1):64-74. PubMed ID: 30506278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway.
    Huang W; Ding X; Ye H; Wang J; Shao J; Huang T
    Neuroreport; 2018 Dec; 29(18):1578-1585. PubMed ID: 30371540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melittin inactivates YAP/HIF-1α pathway via up-regulation of LATS2 to inhibit hypoxia-induced proliferation, glycolysis and angiogenesis in NSCLC.
    Li H
    Clinics (Sao Paulo); 2024; 79():100407. PubMed ID: 38889502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-level laser therapy induces human umbilical vascular endothelial cell proliferation, migration and tube formation through activating the PI3K/Akt signaling pathway.
    Li Y; Xu Q; Shi M; Gan P; Huang Q; Wang A; Tan G; Fang Y; Liao H
    Microvasc Res; 2020 May; 129():103959. PubMed ID: 31734375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.
    Zhao J; Lin E; Cai C; Zhang M; Li D; Cai S; Zeng G; Yin Z; Wang B; Li P; Hong X; Chen J; Zou B; Li J
    Drug Des Devel Ther; 2022; 16():3197-3213. PubMed ID: 36158238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.